Tell me about the eyes.
All had received at least one intravitreal injection within the 6 months prior to surgery. Twenty three eyes showed fluid on OCT prior to surgery but had received an anti-VEGF injection on average 13 days prior to surgery. They monitored the patients OCT's 4-6 weeks after surgery and 6 months after surgery.
What did they find?
There was a significant improvement in the BCVA after cataract surgery and no significant difference in central thickness on OCT.
The take home:
"Patients with both cataracts and wet AMD may safely undergo cataract surgery. Patients with stable preoperative fluid on OCT should be considered for cataract surgery, as these patients did well postoperatively, with no worsening of their neovascular process."
Let's talk glaucoma implants.
Allergan has been working on a sustained-release glaucoma implant.
What is it?
It's called Bimatoprost SR and it's a biodegradable implant that dispenses bimatoprost (aka Lumigan) for at least 4 months. It's injected into the anterior chamber and is visible in the inferior iridocorneal angle where it slowly dispenses medication and degrades.
How much IOP reduction?
In their Phase 3 trial, it reduced IOP by 30% over 12 weeks which is similar to topical prostaglandins.
When will this be a thing?
Not until next year. Allergan plans to submit a new drug application to the FDA in 2019. (via)
This newly designed "retina house" actually blinks.
Also, my apologies for slacking in the month of June. There wasn't a Glance last week and there won't be one this coming week either because I'm in the process of moving from Milwaukee to Boston. But I'll be back at it July 2nd!